TY - JOUR
T1 - Usefulness of 64Cu-ATSM in head and neck cancer
T2 - A preliminary prospective study
AU - Grassi, Ilaria
AU - Nanni, Cristina
AU - Cicoria, Gianfranco
AU - Blasi, Claudio
AU - Bunkheila, Feisal
AU - Lopci, Egesta
AU - Colletti, Patrick M.
AU - Rubello, Domenico
AU - Fanti, Stefano
PY - 2014/1
Y1 - 2014/1
N2 - AIMS: 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) ( 64Cu-ATSM) is a hypoxia-avid, positron emitter radiotracer. The primary aim of this study is to assess the efficacy of pretherapy 64Cu-ATSM PET/CT as a prognostic factor of response to therapy. The secondary aims are to investigate if there is a difference between early and late PET/CT scans and if there is a difference between the biologic tumor volume (BTV) in radiotherapy treatment planning calculated between 64Cu-ATSM and 18F-FDG, and to assess if 64Cu-ATSM is a prognostic marker of disease progression. METHODS: Eleven patients with head and neck cancer treated with chemoradiotherapy were enrolled prospectively; both 64Cu-ATSM and 18F-FDG PET/CT scans before and after treatment were obtained. The 64Cu-ATSM scans were performed after 1 hour (early) and 16 hours (late). RESULTS: All patients had stage III or IV squamous cell head and neck cancer; 7 of 11 patients had nodal metastasis, and 22 cancer foci were detected with 64Cu-ATSM. SUVmax was 16.2 ± 7.9, and there was no significant SUVmax difference between early and late imaging. 18F-FDG SUVmax before therapy was 15.6 ± 9.4, whereas 18F-FDG SUVmax after therapy was 1.5 ± 1.2. Sensitivity and specificity values of 64Cu-ATSM calculated with receiver operating characteristic curves were 100% and 50% considering the SUVmax and 100% and 33% considering the volume, respectively. No difference has been found between the BTV contoured with 64Cu-ATSM and 18F-FDG. CONCLUSIONS: The 64Cu-ATSM scans showed high sensitivity but low specificity in predicting neoadjuvant chemoradiotherapy response. No difference was noted between early and late scans. 18F-FDG and 64Cu-ATSM provided similar results about delineation of BTV.
AB - AIMS: 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) ( 64Cu-ATSM) is a hypoxia-avid, positron emitter radiotracer. The primary aim of this study is to assess the efficacy of pretherapy 64Cu-ATSM PET/CT as a prognostic factor of response to therapy. The secondary aims are to investigate if there is a difference between early and late PET/CT scans and if there is a difference between the biologic tumor volume (BTV) in radiotherapy treatment planning calculated between 64Cu-ATSM and 18F-FDG, and to assess if 64Cu-ATSM is a prognostic marker of disease progression. METHODS: Eleven patients with head and neck cancer treated with chemoradiotherapy were enrolled prospectively; both 64Cu-ATSM and 18F-FDG PET/CT scans before and after treatment were obtained. The 64Cu-ATSM scans were performed after 1 hour (early) and 16 hours (late). RESULTS: All patients had stage III or IV squamous cell head and neck cancer; 7 of 11 patients had nodal metastasis, and 22 cancer foci were detected with 64Cu-ATSM. SUVmax was 16.2 ± 7.9, and there was no significant SUVmax difference between early and late imaging. 18F-FDG SUVmax before therapy was 15.6 ± 9.4, whereas 18F-FDG SUVmax after therapy was 1.5 ± 1.2. Sensitivity and specificity values of 64Cu-ATSM calculated with receiver operating characteristic curves were 100% and 50% considering the SUVmax and 100% and 33% considering the volume, respectively. No difference has been found between the BTV contoured with 64Cu-ATSM and 18F-FDG. CONCLUSIONS: The 64Cu-ATSM scans showed high sensitivity but low specificity in predicting neoadjuvant chemoradiotherapy response. No difference was noted between early and late scans. 18F-FDG and 64Cu-ATSM provided similar results about delineation of BTV.
KW - F-FDG PET/CT
KW - Cu-ATSM PET/CT
KW - Biologic tumor volume (BTV)
KW - Head and neck cancer
KW - Hypoxia
KW - Radiotherapy treatment planning
UR - http://www.scopus.com/inward/record.url?scp=84891560874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891560874&partnerID=8YFLogxK
U2 - 10.1097/RLU.0b013e3182a756f0
DO - 10.1097/RLU.0b013e3182a756f0
M3 - Article
C2 - 24097008
AN - SCOPUS:84891560874
VL - 39
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
SN - 0363-9762
IS - 1
ER -